BlackRock reports 10% QIAGEN N.V. stake in ownership filing (QGEN)
Rhea-AI Filing Summary
BlackRock, Inc. reports owning 20,678,987 shares of QIAGEN N.V. common stock, representing 10.0% of the class as of January 31, 2026. BlackRock has sole voting power over 19,575,569 shares and sole dispositive power over the full 20,678,987 shares.
The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of QIAGEN. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of QIAGEN N.V. does BlackRock’s 13G filing for QGEN indicate it owns?
BlackRock’s Schedule 13G shows it beneficially owns 10.0% of QIAGEN N.V.’s common stock. This ownership level is based on 20,678,987 shares reported as of January 31, 2026, giving BlackRock a significant institutional position in the company.
Does BlackRock’s Schedule 13G for QIAGEN N.V. (QGEN) indicate any intent to influence control?
BlackRock certifies the QIAGEN N.V. shares were acquired and are held in the ordinary course of business. It states they were not acquired and are not held to change or influence control of the issuer, consistent with a passive institutional ownership position.
What is the event date for BlackRock’s reported QIAGEN N.V. ownership in this Schedule 13G?
The Schedule 13G lists January 31, 2026 as the date of the event requiring the filing. Ownership figures such as the 20,678,987 shares and 10.0% of the class are reported as of this date for QIAGEN N.V.’s common stock.